Loading…
TG Therapeutics, Inc. is projected to rise to $84.03 by 2027, a +47% move from its current price of $57.12. TGTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $55.76 | $57.14 | $58.55 | +0.03% |
| Jul 15 | $55.22 | $57.15 | $59.16 | +0.06% |
| Jul 16 | $54.81 | $57.17 | $59.63 | +0.09% |
| Jul 17 | $54.47 | $57.19 | $60.04 | +0.12% |
| Jul 18 | $54.17 | $57.20 | $60.41 | +0.15% |
| Jul 19 | $53.90 | $57.22 | $60.74 | +0.18% |
| Jul 20 | $53.66 | $57.24 | $61.05 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $53.66 | $57.24 | $61.05 | +0.20% |
| Week 2 | $52.36 | $57.35 | $62.83 | +0.41% |
| Week 3 | $51.40 | $57.47 | $64.26 | +0.61% |
| Week 4 | $50.62 | $57.59 | $65.51 | +0.82% |
| Week 5 | $49.96 | $57.71 | $66.66 | +1.03% |
| Week 6 | $49.38 | $57.82 | $67.72 | +1.23% |
| Week 7 | $48.86 | $57.94 | $68.72 | +1.44% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines.
The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
TG Therapeutics, Inc. (TGTX) is currently priced at $59.06 per share and has a market capitalization of $9.04B. It is ranked 990.
The current price outlook is reflected in the forecast, with the 2026 average price of $59.06, rising to $86.88 in 2027, $111.48 in 2028, $127.72 in 2029, and $146.55 in 2030.
From 2027 onward the forecast carries a BULLISH sentiment, with averages climbing to $170.57 in 2031, $181.58 in 2032, $212.12 in 2033, $264.60 in 2034, $304.64 in 2035, $458.90 in 2040, and $1,132.77 in 2050, while the max values reach as high as $1,998.75 in 2050.
A major floor 52.8% below — a decisive break under it would weaken the trend.
The nearest floor, 35.9% below — buyers have tended to step in here.
The nearest ceiling, 3.4% above — a clean break opens room to run.
A major ceiling 28.4% above — clearing it would confirm fresh momentum.
Key TGTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TGTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $57.39 | Sell | $57.14 | Sell |
| MA 10 | $56.03 | Buy | $55.96 | Buy |
| MA 20 | $53.95 | Buy | $53.26 | Buy |
| MA 50 | $45.33 | Buy | $47.03 | Buy |
| MA 100 | $38.59 | Buy | $41.71 | Buy |
| MA 200 | $35.27 | Buy | $37.59 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.73 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 94.84 | Neutral |
| Williams %R (14) | -33.74 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 5.90 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 66.26 | Neutral |
| TRIX (15) | 1.20 | Buy |
| Awesome (5,34) | 9.19 | Buy |
| Ultimate (7,14,28) | 63.08 | Neutral |
| Momentum (10) | 3.49 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 58.89 | Sell |
| ADX (14) | 45.46 | Buy |
| ATR (14) | 1.22 | Info |
The 30-day technical picture is bullish.
RSI14 is 80, SMA50 is $44.88, and SMA200 is $35.16. Support is at $36.64 and resistance at $59.06. The 30-day range runs from $50.43 to $69.17. Annualized volatility is 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.94 | $57.12 | $78.37 | 0% | Neutral | |
| $67.57 | $84.03 | $110.12 | +47% | Bullish | |
| $85.57 | $109.06 | $147.80 | +91% | Bullish | |
| $95.85 | $124.68 | $173.48 | +118% | Bullish | |
| $108.28 | $143.39 | $203.98 | +151% | Bullish | |
| $124.76 | $167.93 | $243.57 | +194% | Bullish | |
| $130.31 | $178.08 | $262.83 | +212% | Bullish | |
| $150.32 | $208.34 | $312.40 | +265% | Bullish | |
| $185.67 | $260.83 | $396.83 | +357% | Bullish | |
| $211.15 | $300.45 | $463.34 | +426% | Bullish | |
| $302.35 | $455.82 | $744.10 | +698% | Bullish | |
| $678.94 | $1,129.26 | $2,003.70 | +18.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $26.94 | $57.12 | $68.00 | +0.00% |
| August 2026 | $48.31 | $56.84 | $68.54 | -0.49% |
| September 2026 | $49.55 | $58.66 | $71.45 | +3.20% |
| October 2026 | $51.33 | $61.11 | $75.06 | +4.17% |
| November 2026 | $51.48 | $61.56 | $76.16 | +0.75% |
| December 2026 | $52.41 | $62.94 | $78.37 | +2.23% |
Click any year to see its month-by-month TGTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
TG Therapeutics, Inc.'s 2026 outlook centres on $57.12, within a $26.94 to $78.37 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TGTX could reach as high as $110.12, with a base case around $84.03 and support toward $67.57 — roughly +47% from $57.12. Buyers look set to stay in control over this stretch.
Expect TGTX to range from $85.57 to $147.80 through 2028. The $109.06 average target implies a +91% move from current prices. That is up +30% on the projected 2027 average. Momentum favours further upside here.
The TGTX price prediction for 2029 points to an average of $124.68 (low $95.85, high $173.48) — a potential gain of +118% on today's $57.12. Buyers look set to stay in control over this stretch.
In 2030, TGTX is projected to trade between $108.28 and $203.98, averaging $143.39 — a potential gain of +151% from today's $57.12. That is up +15% on the projected 2029 average. Momentum favours further upside here.
TG Therapeutics, Inc.'s 2031 outlook centres on $167.93, within a $124.76 to $243.57 range. That is up +17% on the projected 2030 average. That marks a +194% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TGTX could reach as high as $262.83, with a base case around $178.08 and support toward $130.31 — roughly +212% from $57.12. Momentum favours further upside here.
Expect TGTX to range from $150.32 to $312.40 through 2033. The $208.34 average target implies a +265% move from current prices. That is up +17% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TGTX price prediction for 2034 points to an average of $260.83 (low $185.67, high $396.83) — a potential gain of +357% on today's $57.12. Momentum favours further upside here.
In 2035, TGTX is projected to trade between $211.15 and $463.34, averaging $300.45 — a potential gain of +426% from today's $57.12. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
TG Therapeutics, Inc.'s 2040 outlook centres on $455.82, within a $302.35 to $744.10 range. That is up +52% on the projected 2035 average. That marks a +698% change versus current levels. Momentum favours further upside here.
By 2050, TGTX could reach as high as $2,003.70, with a base case around $1,129.26 and support toward $678.94 — roughly +18.8x from $57.12. Buyers look set to stay in control over this stretch.
Investing $1,000 in TGTX today (≈ 17.507003 TGTX) could be worth
$19,769.97
+$18,769.97 (+1877%) by 2050 · US Dollar
Based on the average projected TGTX price of $1,129.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TGTXwould be worth at today's price.
$1,000 invested in TGTX on Jul 10, 2025 (≈ 26.546325 TGTX) would be worth
$1,516.33
+$516.33 (+51.6%) today · 1.52× · US Dollar
Based on a TGTX entry price of $37.67 vs. today's $57.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $53.31 | $1,071.47 | +7.1% |
| 1 month ago | $46.62 | $1,225.23 | +22.5% |
| 3 months ago | $33.73 | $1,693.45 | +69.3% |
| 6 months ago | $27.72 | $2,060.61 | +106.1% |
| 1 year ago | $37.67 | $1,516.33 | +51.6% |
| All time (5.0y) ago | $37.03 | $1,542.53 | +54.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TGTX forecast.
Our base-case forecast reaches $110.00 around 2029.
Implied market cap at $110.00: $16.84B
The multi-year forecast shows a trajectory from a 2026 average price of $59.06 with neutral sentiment to a bullish outlook through 2035 and beyond. In 2026 the min is $26.94 and the max is $81.31 (ROI 0, sentiment NEUTRAL).
Key milestones include a 2030 average price of $146.55 with ROI 148.1 and bullish sentiment. The forecast also flags continued growth with a 2040 average of $458.90 (ROI 677) and a 2050 average of $1,132.77 (ROI 1818).
Across 2031 through 2035 the averages rise from $170.57 to $304.64, and the later horizon shows bullish sentiment with a max path reaching $316.94 in 2033, $401.06 in 2034, $467.96 in 2035, $745.67 in 2040, and $1,998.75 in 2050. These are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
2030_avg: $146.55; min $110.92; max $207.89; ROI 148.1; sentiment BULLISH.
Forecast shows a neutral year in 2026 with an avg price of $59.06, then bullish sentiment from 2027 onward with rising averages to 2050 (avg $1,132.77, max $1,998.75). The data also shows increasing sentiment from 2027 through 2050.
Yes, the maximums in later years reach above $200: 2030 max $207.89, 2031 max $246.63, 2032 max $267.11, 2033 max $316.94, 2034 max $401.06, 2035 max $467.96, 2040 max $745.67, 2050 max $1,998.75.
Low $50.43, High $69.17.
Current price $59.06; market cap $9.04B.
TG Therapeutics, Inc. Community Discussion
0Share your TG Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.